Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Go back to Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress| Consolidated Gems, Inc. (NASDAQ: CGEM) | Delayed: 17.30 +2.27 (15.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.03 | 52 Week High | $0.19 | |||
| Open | $15.27 | 52 Week Low | $0.03 | |||
| Day High | $17.40 | P/E | N/A | |||
| Day Low | $15.26 | EPS | $0.00 | |||
| Volume | 1,496,004 | |||||
